Protalix Common Stock Total Equity from 2010 to 2024
| PLX Stock | USD 1.69 0.03 1.81% |
Common Stock Total Equity | First Reported 1999-03-31 | Previous Quarter 35 K | Current Value 35 K | Quarterly Volatility 50 K |
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Selling General Administrative of 26.7 M or Other Operating Expenses of 31.5 M, as well as many indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 3.4. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
Protalix | Common Stock Total Equity |
Latest Protalix Biotherapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Protalix Biotherapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Protalix Biotherapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Protalix Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 73,703 | |
| Geometric Mean | 48,205 | |
| Coefficient Of Variation | 62.30 | |
| Mean Deviation | 38,983 | |
| Median | 86,000 | |
| Standard Deviation | 45,917 | |
| Sample Variance | 2.1B | |
| Range | 147.4K | |
| R-Value | (0.24) | |
| Mean Square Error | 2.1B | |
| R-Squared | 0.06 | |
| Significance | 0.39 | |
| Slope | (2,445) | |
| Total Sum of Squares | 29.5B |
Protalix Common Stock Total Equity History
About Protalix Biotherapeutics Financial Statements
Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 40.2 K | 62.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.